Kana Sakamoto

1.8k citations
58 papers · 843 indexed · h-index 17
Topics
Hematopoietic Stem Cell Transplantation (20 papers)Neutropenia and Cancer Infections (12 papers)Lymphoma Diagnosis and Treatment (9 papers)
Partner nations
JapanSouth KoreaIreland

In The Last Decade

Kana Sakamoto

56 papers receiving 834 citations

Peers

Kana Sakamoto
Comparison fields: 5 of 66
  • Oncology 374
  • Hematology 333
  • Pathology and Forensic Medicine 207
  • Epidemiology 205
  • Immunology 149
Replace Claude‐Eric Bulabois with:
Claude‐Eric Bulabois France
Bernardino Allione Italy
Pietro Leoni Italy
Jaime Pérez de Oteyza Spain
Peter Johnson United Kingdom
Shun-ichi Kimura Japan
Caterina Giovanna Valentini Italy
S Andresen United States
Marcos J. de Lima United States
A Grañena Spain
Kana Sakamoto relative to Claude‐Eric Bulabois France Claude‐Eric Bulabois's profile →
Citations per field
00.5×
Claude‐Eric Bulabois · 1×
Citations per year

Countries citing papers authored by Kana Sakamoto

Since Specialization
Citations

This map shows the geographic impact of Kana Sakamoto's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kana Sakamoto with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kana Sakamoto more than expected).

Fields of papers citing papers by Kana Sakamoto

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kana Sakamoto. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kana Sakamoto. The network helps show where Kana Sakamoto may publish in the future.

Co-authorship network of co-authors of Kana Sakamoto

This figure shows the co-authorship network connecting the top 25 collaborators of Kana Sakamoto. A scholar is included among the top collaborators of Kana Sakamoto based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kana Sakamoto. Kana Sakamoto is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
#WorkIndexed citations
1 0
2 0
3 2
4 7
5 20
6 4
7 43
8 17
9 26
10 34
11 17
12 2
13 5
14 20
15 27
16 1
17 6
18 26
19 14
20 7

About Kana Sakamoto

Kana Sakamoto is a scholar working on Hematology, Oncology and Transplantation, having authored 58 papers that have together received 843 indexed citations. Recurring topics across this work include Hematopoietic Stem Cell Transplantation (20 papers), Neutropenia and Cancer Infections (12 papers) and Lymphoma Diagnosis and Treatment (9 papers). The work is most often cited by research in Hematology (333 citations), Oncology (374 citations) and Pathology and Forensic Medicine (207 citations). Kana Sakamoto has collaborated with scholars based in Japan, South Korea and Ireland. Frequent co-authors include Kengo Takeuchi, Yoshinobu Kanda, Hideki Nakasone, Shinichi Kako, Misato Kikuchi, Miki Sato, Naoko Tsuyama, Seiji Sakata, Akito Dobashi and Rie Yamazaki. Their work appears in journals such as Blood, PLoS ONE and Leukemia.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026